In 2004, Warren Lammert founded Granite Point Capital, a Boston-based investment firm where he serves as the chief investment officer. Additionally, Warren Lammert is the chairman of Tevard Biosciences, a biotechnology startup that he co-founded.
Focused on developing innovative gene therapies to treat Dravet syndrome, a severe form of epilepsy that commences in infancy, and other rare conditions, Tevard Biosciences is leading the field in transfer RNA (tRNA)-based gene therapies for people with Dravet syndrome. A small RNA molecule, tRNA helps ensure the appropriate amino acid is inserted during protein synthesis inside the cell.
In December 2020, Tevard announced a new partnership with Zogenix, a global biopharmaceutical company that, like Tevard, develops therapies for rare diseases. The companies will collaborate to pioneer new tRNA-based gene therapies to improve treatments for people with Dravet syndrome and other types of epilepsy that have a genetic cause. Zogenix, which is responsible for global commercialization, also brings to the partnership the ability to develop candidates for advanced pre-clinical and clinical studies.
